The global meningococcal vaccine market size is expected to reach USD 5.9 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. Furthermore, according to the European Centre for Disease Prevention and Control (ECDC), it was estimated that in 2017, 3,221 confirmed cases were observed in the EU member states, in which 58% of cases were found in the U.K., France, Spain, and Germany.
In
addition, manufacturers are receiving Break Through Designation (BTD) for the
development of improved vaccines as compared to available therapy.
For instance, in February 2018, GlaxoSmithKline plc received BTD for Bexsero
for extending its use in the age group below 11 years. Such initiatives are
expected to improve meningococcal prevention, which in turn is anticipated to
drive the market.
Initiatives
undertaken by the government to combat the rising incidence of the disease is
anticipated to boost the market growth. For instance, from April 2019, Nimenrix
was made available for free as a part of the National Immunisation Program
(NIP) for the age group 14 to 16 years. Nimenrix is a single dose quadrivalent
meningococcal vaccine that targets serogroups A, C, W & Y.
In
addition, rising awareness programs focused on prevention of the target disease
is expected to fuel market growth. For instance, in April 2019, the National
Day of Action against Meningitis B was launched by the Meningitis B Action
Project on World Meningitis Day to improve awareness of meningitis regarding
available vaccines such as MenACWY and MenB among healthcare professional,
students, and parents.
Furthermore,
the government provision of free vaccination to reduce the spread of the target
disease is anticipated to boost the market growth. For instance, in November
2018, the government of New Zealand started a free vaccination program in
Northland for infants and children.
Non-profit
organizations entering into strategic initiatives such as partnering,
alliances, and others to improve access to new vaccines for vulnerable children
is anticipated to drive the market. For instance, Gavi is a vaccine alliance
formed between UNICEF, World Health Organization, the Bill and Melinda Gates
Foundation, and the World Bank to help boost economies of low-income countries
and improve access to under-used vaccines for children suffering from
meningitis.
Moreover,
clinical trials conducted on teenagers to develop novel meningococcal vaccines
are expected to drive the market. For instance, in March 2018, the National
Health Service launched a Meningitis B vaccine trial for teenagers and
recruited 24,000 volunteers of age group 16 to 18 years for this study. This
clinical trial was funded and supported by the National Institute for Health
Research (NIHR).
The
availability of vaccines at lower prices in countries with an increasing
prevalence of meningococcal diseases is anticipated to fuel the revenue of the
manufacturers and drive the market. For instance, under the Meningitis Vaccine
Project, MenAfriVac costs less than USD 0.5 per dose.
Full Research Report On Meningococcal Vaccine Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/meningococcal-vaccines-market
Meningococcal
Vaccine Market Report Highlights
- In 2019,
Bexsero was the largest-revenue holding brand in the market owing to its
stronger demand in Europe and studies showing a decrease in meningitis
cases
- The
quadrivalent segment is expected to witness the fastest growth over the
forecast period due to its ability to target four serogroups and the
availability of vaccines such as Menactra, Menveo, and Nimenrix
- In the case
of the age group segment, infants (0 to 2 years) are expected to witness a
significant CAGR owing to the increasing prevalence of meningitis in the
age group 9 months to 11 years
- Asia Pacific
is projected to witness the fastest growth during the forecast period
owing to the high unmet needs and rising healthcare expenditure
- North America
dominated the market in 2019 due to the presence of key players and rising
initiatives to raise awareness among healthcare professionals and patients
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/meningococcal-vaccines-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment